Still here and still short this POS. JNJ saved the day friday.Short a BIO over a long weekend is not the smartest thing I have ever done. STOLICHNAYA and orange juice are a good sub for sleeping pills.
With ISIS so powerful with cash relatively speaking this is why OGXI is not compromised compared to other biotechs, this taken from the ISIS board:
age-related macular degeneration 26-May-09 01:53 am LONDON, May 24 (Reuters) - Suitors for British biotech company Intercytex include U.S. pharmaceutical giant Pfizer, the Sunday Times reported, without citing sources. Intercytex said last week it had had received "a number of approaches" from unnamed parties, sending its shares up over 50 percent. Pfizer's interest is based on the work Intercytex is doing on a research project to cure age-related macular degeneration, which causes blindness, the newspaper said.
This could result in a bump for ICo and ISIS:
INFO on ICo:
Isis Likes ICo: Isis Pharmaceuticals said it increased its ownership in iCo Therapeutics. The Carlsbad-based drug maker said it has acquired 2.2 million units of iCo consisting of one share per unit and partial warrants exercisable at 30 cents a share until Feb. 8. ICo is a Vancouver, British Columbia, Canada-based biotech.
Following completion of a private placement Feb. 9, Isis now owns 4 million shares of iCo, or 14 percent.
In August, Isis granted iCo exclusive rights to develop and commercialize ISIS 13650, a second generation antisense drug. ICo renamed the experimental drug iCo-007 and is developing it for the treatment of various eye diseases, including age-related macular degeneration
As further argument I don't think that management at OGXI are purposely going to try dodging payings ISIS 30% upfront fees, especially if somehow ISIS can keep them from suffering too much further dilution. The people running OGXI seem to me to be pretty brilliant. t